Article Type
Changed
Tue, 08/10/2021 - 12:46
Display Headline
MS CONFERENCE NEWS

MS CONFERENCE NEWS

Contents

  • Common MS treatment wears off more quickly in Black patients
  • A less expensive, more convenient treatment option for MS?
  • Investigational drug reduces brain lesions in highly active MS
  • Evobrutinib may lower nerve damage biomarker levels
  • Disease progression and therapy response vary in MS by ethnicity
  • Some MS treatments may heighten COVID risk
  • Natalizumab postinfusion reactions
Publications
Topics
Sections

MS CONFERENCE NEWS

Contents

  • Common MS treatment wears off more quickly in Black patients
  • A less expensive, more convenient treatment option for MS?
  • Investigational drug reduces brain lesions in highly active MS
  • Evobrutinib may lower nerve damage biomarker levels
  • Disease progression and therapy response vary in MS by ethnicity
  • Some MS treatments may heighten COVID risk
  • Natalizumab postinfusion reactions

MS CONFERENCE NEWS

Contents

  • Common MS treatment wears off more quickly in Black patients
  • A less expensive, more convenient treatment option for MS?
  • Investigational drug reduces brain lesions in highly active MS
  • Evobrutinib may lower nerve damage biomarker levels
  • Disease progression and therapy response vary in MS by ethnicity
  • Some MS treatments may heighten COVID risk
  • Natalizumab postinfusion reactions
Publications
Publications
Topics
Article Type
Display Headline
MS CONFERENCE NEWS
Display Headline
MS CONFERENCE NEWS
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 08/10/2021 - 12:45
Un-Gate On Date
Tue, 08/10/2021 - 12:45
Use ProPublica
CFC Schedule Remove Status
Tue, 08/10/2021 - 12:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article